Background
Long-acting cabotegravir (CAB-LA) plus long-acting rilpivirine (RPV-LA) are approved for maintenance of viral suppression in adults and adolescents >35kg with HIV-1 infection. IMPAACT 2036 (CRAYON) is a Phase I/II, multi-center, open-label, non-comparative study to evaluate safety, tolerability, acceptability and pharmacokinetics (PK) of oral (PO) and intramuscular (IM) CAB-LA+RPV-LA in children 2-<12 years, living with HIV-1. Here we present the first report of CAB-LA+RPV-LA in children from interim Week (W)12 data.
Methods
Virologically suppressed (viral load <50 copies/mL) children living with HIV-1 on stable combination antiretroviral therapy (cART) were enrolled into weight-band (WB) 1 (35-<40kg), 2 (25-34.9kg) or 3 (20-24.9kg). After discontinuing background cART, participants received PO CAB+RPV through W4, followed by IM CAB-LA+RPV-LA injections every 4 weeks (Q4W), per WB dosing table. PK samples were drawn at W2 (to assess PO dosing) and W4, 5, 6, 8, 9 and 12 (to assess LA dosing).
Results
35 participants were enrolled: 8 in WB 1, 16 in WB 2 and 11 in WB 3; one prematurely discontinued study drug due to anxiety associated with painful procedures. The safety analysis set included 20 children who completed treatment through W12 before the safety interim analysis freeze date. Median (Q1, Q3) age and weight were 10 years (8, 10.5) and 26.2 kg (22.2, 29.9); 60% were female; 25% were Asian, 75% were Black or African American.
8 (40%) children had a Grade ≥1 adverse event (AE) through W12, all ≤Grade 3. Frequent AEs included injection site pain (n=3, all Grade 1), headache (n=3), pyrexia (n=2), oropharyngeal pain (n=2) and cough (n=2). One child (5%) had two Grade 3 AEs which resolved. Participants maintained virologic suppression through W12.
34 participants contributed to the PK analysis, with 24 completing W12 before the PK interim analysis freeze date. Median (Q1, Q3) AUCs during oral lead-in (n=34) were 109 000 (86 000, 130 000) ng*h/mL for CAB-PO and 3086 (2351-4440) ng*h/mL for RPV-PO. Median (Q1, Q3) pre-dose concentrations at W12 (n=24) were 2160 (1440, 3430) ng/mL for CAB-LA and 52 (43, 66) ng/mL for RPV-LA (Figure 1). These values met protocol-defined acceptable criteria for both drugs by PO and IM routes.
Conclusions
Administration of PO CAB+RPV followed by Q4W IM CAB-LA+RPV-LA in children 20-<40 kg achieved exposure concentrations comparable to adolescents and adults receiving this regimen. No new or unanticipated safety concerns were identified.